Ticagrelor, an inhibitor of the ADP–P2Y12 axis, was demonstrated to boost chemotherapeutic efficacy synergized with chemotherapeutic agents in pancreatic cancer cells, which was mediated by reducing EGF-dependent AKT activation (Elaskalani et al., 2020). The gene discussed is AKT1; the disease is familial pancreatic carcinoma.